Business Context and Reporting Period
This Form 8-K is a current report filed by Veracyte, Inc. on November 16, 2015, regarding events occurring on November 12, 2015. The filing discloses a change in the composition of the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Election: Effective November 12, 2015, the Board of Directors elected Tina S. Nova, Ph.D., as a new director.
- Committee Assignment: Dr. Nova was appointed as Chairman of the Regulatory and Compliance Committee.
- Compensation: Dr. Nova will receive standard non-employee director cash and equity compensation, plus an additional $10,000 annually for her role as Committee Chairman.
Management Commentary and Background
Dr. Nova is a life sciences industry veteran with extensive experience in genomics-based businesses. Her recent roles include President and CEO of Molecular Stethoscope, Inc. (since October 2015) and Senior Vice President of Illumina Inc.'s oncology business unit (July 2014 to August 2015). She is a co-founder of Genoptix, Inc., which was acquired by Novartis AG in 2011. She currently serves on the boards of Arena Pharmaceuticals, Inc. and the Rady Pediatric Genomics and Systems Medicine Institute.
Investor Verification Checklist
- Verify the effective date of Dr. Nova's board membership (November 12, 2015).
- Confirm the specific compensation structure for non-employee directors as detailed in the 2015 Proxy Statement.
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.